Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Dr. Manish Shah on Treatment Options for Patients With Locally Advanced Stomach Cancer
February 2nd 2016Manish Shah, MD, Bartlett Family Associate Professor of Medicine, director, Gastrointestinal Oncology Program, Weill Cornell Medical College, discusses doing more than just surgery for patients with locally advanced stomach cancer.
Read More
Dr. Kenneth Wang on Forgoing Screening for Barrett's Esophagus
February 2nd 2016Kenneth Wang, MD, director of the Advanced Endoscopy Group and Esophageal Neoplasia Clinic, Mayo Clinic, discusses his opposition for Barrett's esophagus screening as a preventative measure for esophageal adenocarcinoma.
Watch
Dr. Keith Wilson on the Role of Helicobacter Pylori in Gastrointestinal Cancer
January 30th 2016<div style="color:#003668"><em>"When there is a mismatch between the human genetics and bacterial genetics, this may be one of the factors that leads to gastrointestinal cancer."<p align="right"><span style="color:#747474">- Keith Wilson, MD</span></em></div></p>
Watch
Ensituximab (NPC-1C) Shows Promise and Good Tolerability in Refractory Metastatic Colorectal Cancer
January 29th 2016In patients with chemotherapy-refractory metastatic colorectal cancer (mCRC), ensituximab (NPC-1C), a chimeric immunoglobulin IgG1 monoclonal antibody, produced stable disease in almost half the patients in a phase II study, without contributing toxicity.
Read More
Dr. Georgia L. Wiesner on the Importance of Genetic Testing for Colorectal Cancer
January 27th 2016Georgia L. Wiesner, MD, MS, director, Clinical and Translational Hereditary Cancer Program, Ingram Professor of Cancer Research, professor of Medicine, cancer geneticist, Vanderbilt-Ingram Cancer Center, discusses the role genetic testing for colorectal cancer (CRC) plays in families.
Watch
Second-Line Treatment for Metastatic Pancreatic Cancer Feasible and Beneficial
January 27th 2016Second-line treatment of metastatic pancreatic cancer proved to be feasible and beneficial, particularly for patients who received nab-paclitaxel in addition to gemcitabine, according to extension data from a phase III trial.
Read More
Analysis Shows Pancreatic Cancer Survival Rates Lower in Real World Than Clinical Trials
January 27th 2016Patients with pancreatic adenocarcinoma enrolled on clinical trials have "profoundly improved survival" compared with patients in the general population, suggesting that oncologists who use trial data to prognosticate may be missing the mark, according to researchers whose work was presented at the 2016 Gastrointestinal Cancers Symposium.
Read More
Regorafenib Retains Safety and Efficacy in Subgroup Analysis of CONSIGN
January 27th 2016The safety and efficacy profile of regorafenib in patients with previously treated colorectal cancer (CRC) is similar between US patients and the global study population enrolled in the phase IIIb CONSIGN study, according to Udit Verma, MD, at the 2016 Gastrointestinal Cancers Symposium.
Read More
Avelumab Shows Clinical Activity in Advanced Gastric and GEJ Cancer
January 27th 2016Avelumab, an investigational anti-PD-L1 antibody, showed clinical activity as both a second-line and maintenance therapy in patients, with unresectable gastric or gastroesophageal junction (GEJ) cancer, according to data from a phase Ib presented at the 2016 Gastrointestinal Cancers Symposium.
Read More
Oral Stemness Inhibitor Shows Responses in Heavily Pretreated Metastatic Pancreatic Cancer
January 27th 2016An orally administered first-in-class cancer stemness inhibitor, BBI608, administered twice daily with weekly paclitaxel has promising activity in patients with refractory, heavily pretreated metastatic pancreatic cancer; particularly in patients who are taxane naive.
Read More
Carboplatin/Paclitaxel Neoadjuvant Regimen Worthy of Phase II Investigation in Esophageal Cancer
January 26th 2016Carboplatin/paclitaxel-based chemoradiotherapy (CarPacRT) has sufficient activity to progress into phase II clinical trials as neoadjuvant treatment for patients with resectable esophageal cancer.
Read More
Nivolumab Exhibits Clinical Activity in Gastric Cancer
January 26th 2016Nivolumab (Opdivo) produced an overall response rate (ORR) of 14% with an acceptable safety profile in patients with gastric or gastroesophageal junction (GEJ) cancer, according to data from the phase I/II CheckMate-032 trial.
Read More
Updated Data Shows Sustained OS Advantage for Liposomal Irinotecan in Pancreatic Cancer
January 21st 2016Combining liposomal irinotecan (nal-IRI; MM-398; Onivyde) with 5-fluorouracil (5-FU) plus leucovorin dropped the risk of death in patients with metastatic pancreatic cancer by 25% following progression on a gemcitabine-based regimen, according to updated data from the phase III NAPOLI-1 trial.
Read More
Neoadjuvant Radiation Regimen Efficacious, Less Toxic in Patients With Rectal Cancer
January 20th 2016Preoperative treatment with short-course radiation therapy plus 3 cycles of chemotherapy boosted overall survival (OS) and generated fewer adverse events (AEs) compared to standard chemoradiation for patients with locally advanced rectal cancer.
Read More
Everolimus Becomes the New Standard of Care for Patients With GI NETs
January 20th 2016Patients with either gastrointestinal (GI) neuroendocrine tumors (NETs) or NETs of unknown primary origin experienced a 40% or more decrease in their risk of disease progression when treated with everolimus (Afinitor), according to a subanalysis of the phase III RADIANT-4 trial.
Read More
Lu-Dotatate Continues to Offer Major Benefits to Patients With Midgut NETs
January 20th 2016Patients with advanced midgut neuroendocrine tumors (NETs) will continue to see major therapeutic benefits from the peptide receptor radionuclide therapy Lu-Dotatate (Lutathera), including an improvement in overall survival and the reduction of progression or death risk by 79%.
Read More
FDA Approves Non-Alcohol Formulation of Docetaxel for Multiple Cancer Types
December 29th 2015The FDA has approved a new treatment consisting of a non-alcohol formulation of docetaxel in patients with breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.
Read More
Surprising Findings in Intratumor Heterogeneity Could Impact Cancer Treatment
December 23rd 2015A new study has analyzed intratumoral heterogeneity (ITH) in 12 cancer types and found a "tolerable" level of genomic instability, independent of cancer type, beyond which a cancer may become less aggressive.
Read More
Novel Immunotherapy for Pancreatic Cancer May Allow for Resection of the Unresectable
December 16th 2015The phase III PILLAR trial studying the novel immunotherapy, algenpantucel-L combined with chemotherapy in patients with locally advanced, unresectable pancreatic cancer, has completed enrollment with over 300 patients.
Read More
Stakeholders Urge Congress to Pass Screening Act for Colorectal Cancer
November 13th 2015A number of colorectal cancer care advocacy groups and the American Cancer of Radiology are lobbying Congress to pass the CT Colonography Screening for Colorectal Cancer Act, an initiative that could lower costs and increase screening rates.
Read More
Soil Bacteria Reduces Growth of Colorectal Cancer Cells in Preclinical Study
November 13th 2015Dead bacteria cells and bacteria excretions from Clostridium sporogenes have successfully been used to kill colorectcal cancer cells in a preclinical study performed by researchers at the Nanyang Technological University in Singapore.
Read More
Dr. John Zalcberg on Regorafenib in Refractory Advanced Oesophago-Gastric Cancer Patients
November 11th 2015John Zalcberg, PhD, medical oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia, talks about the poor prognosis of refractory advanced oesophago-gastric cancer (AOGC) patients and how regorafenib could benefit those patients.
Watch